CLINICAL_TRIALS
trial_result
· 2014-05-12
Clinical Trial Update: To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen [Phase 2]
Summary
Phase 2 trial evaluating sipuleucel-T manufactured with different concentrations of PA2024 antigen in prostate cancer; results completed and posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dendreon | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-05-12